InsiderSignal.AI

InsiderSignal.ai

NMRA - Neumora Therapeutics, Inc.

Insider Purchase by Arch Venture Partners X, LLC (10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

3 months ago, Arch Venture Partners X, LLC, serving as 10% owner at Neumora Therapeutics, Inc. (NMRA), purchased 1,915,700 shares at $2.61 per share, for a total transaction value of $4,999,977.00. Following this transaction, Arch Venture Partners X, LLC now holds 33,847,838 shares of NMRA.

This purchase represents a 6.00% increase in Arch Venture Partners X, LLC's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, October 27, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, October 29, 2025, 2 days after the trade was made.

Neumora Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Arch Venture Partners X, LLC

10%

Arch Venture Partners X, LLC is a venture capital entity affiliated with ARCH Venture Partners, a leading early-stage investment firm founded in 1986 in Chicago, Illinois, specializing in building and funding companies from breakthrough science, primarily in life sciences, biotechnology, and related deep-tech fields.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[3]](https://www.archventure.com)[[6]](https://www.archventure.com/about/) The firm, with over $10 billion in assets under management, focuses on company creation at the seed and Series A stages, partnering with scientists from top institutions to commercialize disruptive technologies aimed at preventing, detecting, and treating diseases.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[4]](https://www.privateequityinternational.com/institution-profiles/arch-venture-partners.html) Headquartered in Chicago with offices in Seattle, San Francisco, and Dublin, ARCH has a portfolio exceeding 130 active companies and has raised significant funds, including $1.46 billion in 2022 for biotechnology investments.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[7]](https://www.archventure.com/arch-venture-partners-announces-1-46-billion-raised-in-two-new-funds-to-invest-in-transformative-biotechnology-companies/) As a corporate insider, Arch Venture Partners X, LLC recently traded representing 10% ownership in Neumora Therapeutics, Inc. (NMRA), reflecting its active role in healthcare therapeutics investments.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[5]](https://www.archventure.com/portfolio/)

View full insider profile →

Trade Price

$2.61

Quantity

1,915,700

Total Value

$4,999,977.00

Shares Owned

33,847,838

Trade Date

Monday, October 27, 2025

118 days ago

SEC Filing Date

Wednesday, October 29, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Neumora Therapeutics, Inc.

Company Overview

No company information available
View news mentioning NMRA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/979120

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime